Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma

Cancer Letters(2019)10.1016/j.canlet.2019.07.004Source: DataRank Database

Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma is a research paper published in Cancer Letters (2019). On theSindex it has a DataRank of 0.612. It has been cited 58 times.

N/A

0.612DataRank · unranked

Scored on demand from live citation data

58 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 6.26)OA: hybridTopics (53)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.612

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (9)

Anne van Wijngaarden,Arjan Kol,Gert J. Meersma,Mathilde Jalving ORCID,René Bernards ORCID

Live enrichment

PubMed:31319139 OpenAlex:https://openalex.org/W2958505263

KWF Kankerbestrijding

Grant: RUG 2012-5477

Cock-Hadders foundation

FWCI

6.26

Citation Percentile

1.0%

Citation Trend

2019

2020

2021

2022

2023

2024

2025

hybridLicense: cc-by

journalhttps://www.sciencedirect.com/science/article/pii/S0304383519304008/pdf

publisherhttps://www.sciencedirect.com/science/article/pii/S0304383519304008/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0304383519304008?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0304383519304008?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.canlet.2019.07.004

Fields of Study

Ovarian cancer diagnosis and treatmentChromatin Remodeling and CancerCancer Mechanisms and Therapy

MeSH Terms

AdenineAnimalsAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesBenzoxazolesDose-Response Relationship, DrugDrug SynergismFemaleHumansIndazolesMice, NudeMorpholinesOvarian NeoplasmsPhosphorylationPyrimidinesSulfonamidesTumor Cells, CulturedBiomarkers, TumorGene Expression Regulation, NeoplasticApoptosisAdenocarcinoma, Clear CellPhosphatidylinositol 3-KinasesXenograft Model Antitumor AssaysProtein Kinase InhibitorsCell ProliferationProto-Oncogene Proteins c-aktMiceTOR Serine-Threonine Kinases

Keywords

PI3K/AKT/mTOR pathwaymTORC1Protein kinase BCancer researchMAPK/ERK pathwayTolerabilityKinaseMedicinemTORC2Ovarian cancerBiologyPharmacologyCancerSignal transductionCell biologyInternal medicineAdverse effectMAPKCombination treatmentPi3k/akt/mtorOvarian Clear Cell CarcinomaPdx Models

Sustainable Development Goals

SDG 0: Good health and well-being

Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma

FAIR Checklist

DataRank Breakdown

Authors (9)

Funding (2 grants)

Impact

Open Access

Topics